These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
611 related articles for article (PubMed ID: 28576423)
1. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of Gauthé M; Belissant O; Girard A; Zhang Yin J; Ohnona J; Cottereau AS; Nataf V; Balogova S; Pontvert D; Lebret T; Guillonneau B; Cussenot O; Talbot JN Prog Urol; 2017; 27(8-9):474-481. PubMed ID: 28576423 [TBL] [Abstract][Full Text] [Related]
2. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of Chevalme YM; Boudali L; Gauthé M; Rousseau C; Skanjeti A; Merlin C; Robin P; Giraudet AL; Janier M; Talbot JN Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2935-2950. PubMed ID: 33416958 [TBL] [Abstract][Full Text] [Related]
4. von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of Dong L; Zhu Y; Xin M; Dong B; Pan J; Liu J; Amend SR; Xue W; Pienta KJ; Rowe SP Med Oncol; 2020 Sep; 37(10):89. PubMed ID: 32920666 [TBL] [Abstract][Full Text] [Related]
6. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024 [TBL] [Abstract][Full Text] [Related]
7. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes. Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066 [TBL] [Abstract][Full Text] [Related]
8. Efficacy, Predictive Factors, and Prediction Nomograms for Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059 [TBL] [Abstract][Full Text] [Related]
9. The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of Metser U; Chua S; Ho B; Punwani S; Johnston E; Pouliot F; Tau N; Hawsawy A; Anconina R; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Pond G; Scott AM; Tunariu N; Sidhu H; Emmett L J Nucl Med; 2019 Sep; 60(9):1253-1258. PubMed ID: 30902875 [TBL] [Abstract][Full Text] [Related]
13. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995 [TBL] [Abstract][Full Text] [Related]
14. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282 [TBL] [Abstract][Full Text] [Related]
15. Prospective, Multisite, International Comparison of Emmett L; Metser U; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Punwani S; Pond G; Chua S; Ho B; Johnston E; Pouliot F; Scott AM J Nucl Med; 2019 Jun; 60(6):794-800. PubMed ID: 30442757 [TBL] [Abstract][Full Text] [Related]
16. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. De Bari B; Mazzola R; Aiello D; Fersino S; Gregucci F; Alongi P; Nicodemo M; Cavalleri S; Salgarello M; Alongi F Radiol Med; 2018 Sep; 123(9):719-725. PubMed ID: 29687208 [TBL] [Abstract][Full Text] [Related]
17. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen ( Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951 [TBL] [Abstract][Full Text] [Related]
18. Value of García JR; Compte A; Buxeda M; Mourelo S; Soler M; Blanch A; Valls E; Riera E Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):197-203. PubMed ID: 32165153 [TBL] [Abstract][Full Text] [Related]
19. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446 [TBL] [Abstract][Full Text] [Related]
20. [Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma]. Moussaid Y; Bonardel G; Jacob J; Métivier D; Gontier E; Bauduceau O; Durand X; Fayolle M; Houlgatte A; Foehrenbach H; Védrine L; Chargari C Cancer Radiother; 2013; 17(4):259-64. PubMed ID: 23702489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]